To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases